Manuscript submission / Evaluation
Click here to download Turk J Phys Med Rehab's ENDNOTE Style File
Authors :
Title :
Summary :
Keyword :
Open Access
Turkish Journal of Physical Medicine and Rehabilitation 2022 , Vol 68 , Num 2

A case of Guillain-Barre syndrome after the second dose of AstraZeneca COVID-19 vaccination

Hanieh Bazrafshan 1 ,Leila Sadat Mohamadi Jahromi 2 ,Reyhaneh Parvin 3 ,Alireza Ashraf 4
1 Department of Neurology, Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2 Department of Physical Medicine and Rehabilitation, Shiraz Medical School, Shiraz University of Medical Sciences, Faghihi Hospital, Shiraz, Iran
3 Department of Physical Medicine and Rehabilitation, Shiraz University of Medical Sciences, Faghihi Hospital, Shiraz, Iran
4 Department of Physical Medicine and Rehabilitation, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran DOI : 10.5606/tftrd.2022.9984 Coronavirus disease 2019 (COVID-19) is a novel virus that primarily involves the respiratory system. Due to the COVID-19 pandemic, an extensive vaccination program is underway worldwide. Herein, we present a 68-year-old woman with paresthesia of both hands associated with gait instability, which started three to four days after receiving the second dose of Oxford/AstraZeneca vaccine against the COVID-19 infection. The acute inflammatory demyelinating polyradiculoneuropathy subtype of the Guillain-Barre syndrome, which is the most common subtype, was diagnosed. Regardless of the beneficial effects of the vaccines, this case report aimed to evaluate their severe complications, such as Guillain-Barre syndrome, to reduce their occurrence in the future. Keywords : AstraZeneca vaccine, COVID-19, Guillain-Barre syndrome